At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
somatostatindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Measurement of Glucose/Glycogen Metabolism in Humans Using Magnetic Resonance at 4 or 7 Tesla
In Brief
A Phase 2 clinical trial evaluating somatostatin for Type 1 Diabetes. Completed, enrolled 10 participants across 1 site.
Detailed Summary
The long-range goal of this project is to determine the effects of diabetes and the hypoglycemic consequences of intensive therapy on in vivo brain glucose metabolism in humans. We will measure brain glycogen turnover and content in normal controls and subjects with diabetes under conditions of modest hyper-and hypoglycemia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2004
First PostedNov 2008
Primary CompletionDec 2017
TodayJul 2026
First PostedNov 6, 2008
Enrollment StartDec 1, 2004
Primary CompletionDec 1, 2017
TodayJul 2, 2026
Enrollment to primary: 13 yearsPosted 17.7 years ago
Interventions
somatostatindrug
Somatostatin may be used to suppress endogenous insulin secretion